AIM Vaccine Co., Ltd.
艾美疫苗股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 06660)

ADJOURNMENT OF EXTRAORDINARY GENERAL MEETING AND CHANGE OF BOOK CLOSURE PERIOD

Reference is made to the circular of the Company (the "**Circular**") and the notice of the 2026 second extraordinary general meeting (the "**EGM**") of the Company (the "**Notice**") both dated August 18, 2026 in relation to, among others, the proposed amendments to the issuance of Domestic Unlisted Shares under specific mandate, connected transaction and subscription in respect of the proposed issuance of Domestic Unlisted Shares. Unless otherwise defined herein, terms used in this announcement have the same meaning as defined in the Circular.

ADJOURNMENT OF EXTRAORDINARY GENERAL MEETING

As set out in the Circular and the Notice, the proposed amendments to the Approved Mandate, the connected transaction in respect of the proposed issuance of Domestic Unlisted Shares to Tibet Bohai and the subscription in respect of the proposed issuance of Domestic Unlisted Shares were proposed to be considered and, if thought fit, approved by the Shareholders at the EGM scheduled to be held at 2:00 p.m. on Monday, September 7, 2026 at meeting room, 10/F, Gangwu Building, No. 1 Fenghe Road, Lujiazui Street, Pudong New District, Shanghai, the PRC.

Pursuant to Rule 13.73 of the Listing Rules, the Company shall provide the Shareholders with any material information on the subject matter to be considered at a general meeting that comes to the Directors' attention after the circular is issued. The Company must provide the information either in a supplementary circular or by way of an announcement not less than 10 business days before the date of the relevant general meeting to consider the subject matter. The meeting must be adjourned before considering the relevant resolution to ensure compliance with this 10 business day requirement by the chairman or, if that is not permitted by the issuer's constitutional document, by resolution to that effect.

The Company is currently contemplating to amend the issuance plan of the Issuance (the "**Amendments to the Proposed Amended Mandate**"). The Board considers that the Amendments to the Proposed Amended Mandate would be material information for the Shareholders to consider at the EGM. Therefore, the Board considers that it would be appropriate and prudent to adjourn the EGM, and provide additional information regarding the Amendments to the Proposed Amended Mandate to the Shareholders pursuant to Rule 13.73 of the Listing Rules. Accordingly, the Company announces that the EGM will be adjourned until further notice and the resolutions set out in the Notice will not be put forward for the Shareholders' consideration.

The Company will publish announcement(s) to inform the Shareholders of any further updates as and when appropriate. The Company will also revise the Circular, the Notice, the proxy form and other related documents as soon as practicable.

CHANGE OF BOOK CLOSURE PERIOD

Due to the adjournment of the EGM, the period during which the register of members will be closed in order to determine the identity of the Shareholders who are entitled to attend the EGM (during which period no share transfers will be registered) will also be changed. The register of members will no longer be closed from Wednesday, September 2, 2026 to Monday, September 7, 2026 (both days inclusive) as set out in the Circular. The revised period during which the register of members will be closed will be announced together with the revised date of the EGM.

For details of the revised date, time and venue of the EGM, the resolutions to be considered and other related matters, please refer to the notice and circular in relation to the EGM to be published by the Company in due course.

By order of the Board
AIM Vaccine Co., Ltd.
Chairman of the Board and CEO
Mr. Yan ZHOU

Beijing, the PRC, September 1, 2026

As at the date of this announcement, the Board comprises Mr. Yan ZHOU, Mr. Xin ZHOU, Mr. Shaojun JIA, Mr. Wen GUAN, Mr. Jie ZHOU and Ms. Ling LIU as executive directors; Mr. Jichen ZHAO as a non-executive director; and Professor Ker Wei PEI, Mr. Xiaoguang GUO, Mr. Hui OUYANG and Mr. Weicai SHAO as independent non-executive directors.